Brigitta Derendinger, Anzaan Dippenaar, Margaretha de Vos, Stella Huo, Rencia Alberts, Rebecca Tadokera, Jason Limberis, Frik Sirgel, Tania Dolby, Claudia Spies, Anja Reuter, Megan Folkerts, Christopher Allender, Darrin Lemmer, Annelies Van Rie, Sebastien Gagneux, Leen Rigouts, Julian Te Riele, Keertan Dheda, David M Engelthaler, Robin Warren, John Metcalfe, Helen Cox, Grant Theron
BACKGROUND: Bedaquiline is a life-saving tuberculosis drug undergoing global scale-up. People at risk of weak tuberculosis drug regimens are a priority for novel drug access despite the potential source of Mycobacterium tuberculosis-resistant strains. We aimed to characterise bedaquiline resistance in individuals who had sustained culture positivity during bedaquiline-based treatment. METHODS: We did a retrospective longitudinal cohort study of adults (aged ≥18 years) with culture-positive pulmonary tuberculosis who received at least 4 months of a bedaquiline-containing regimen from 12 drug-resistant tuberculosis treatment facilities in Cape Town, South Africa, between Jan 20, 2016, and Nov 20, 2017...
November 3, 2023: The Lancet. Microbe